DALLAS, Nov. 25, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on NexMed Inc. (Nasdaq:NEXM) should be of particular interest to other drug companies: Pfizer Inc. (NYSE:PFE), Adamis Pharmaceuticals Corp. (OTCBB:ADMP) and Amgen Inc. (Nasdaq:AMGN).
It is available at: http://www.beaconequity.com/i/NEXM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
NexMed Inc. (NEXM) is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin.
In the report, the analyst notes:
"NEXM earlier this month announced that it raised $750,000 in gross proceeds from the issuance of new convertible notes due December 31, 2011, which are secured by a mortgage on NEXM's facility in East Windsor, New Jersey.
"NEXM in late October announced that news regarding its request for a hearing concerning its possible delisting from the Nasdaq Capital Market. NEXM's stock will continue to trade on the Nasdaq Capital Market pending a final decision by Nasdaq, which typically occurs within four to five weeks after the completion of the formal hearing that took place November, 12, 2009. As announced on October 14, 2009, NEXM received a notice from Nasdaq indicating that it did not comply with the minimum $2.5 million stockholders' equity requirement for continued listing set forth in Marketplace Rule 5550(b)."
To read the entire report visit: http://www.beaconequity.com/i/NEXM
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com
